for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nektar Therapeutics

NKTR.O

Latest Trade

16.35USD

Change

-0.21(-1.27%)

Volume

406,801

Today's Range

16.25

 - 

16.61

52 Week Range

12.92

 - 

26.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.56
Open
16.47
Volume
406,801
3M AVG Volume
18.38
Today's High
16.61
Today's Low
16.25
52 Week High
26.75
52 Week Low
12.92
Shares Out (MIL)
183.80
Market Cap (MIL)
3,005.15
Forward P/E
-5.39
Dividend (Yield %)
--

Next Event

Q3 2021 Nektar Therapeutics Earnings Release

Latest Developments

More

Nektar Therapeutics Q2 Loss Per Share $0.69

Nektar Therapeutics Reports First Quarter 2021 Financial Results

Nektar Therapeutics Reports Q4 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.

Industry

Business Services

Contact Info

455 Mission Bay Blvd S

SAN FRANCISCO, CA

94158-2158

United States

+1.415.4825300

http://www.nektar.com

Executive Leadership

Robert B. Chess

Independent Chairman of the Board

Howard W. Robin

President, Chief Executive Officer, Director

Gilbert M Labrucherie

Chief Financial Officer, Chief Operating Officer, Senior Vice President

Jillian B. Thomsen

Senior Vice President - Finance, Chief Accounting Officer

Mark A. Wilson

Senior Vice President, General Counsel

Key Stats

2.36 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.2K

2019

0.1K

2020

0.2K

2021(E)

0.1K
EPS (USD)

2018

3.780

2019

-2.520

2020

-2.490

2021(E)

-3.032
Price To Earnings (TTM)
--
Price To Sales (TTM)
28.49
Price To Book (MRQ)
3.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.99
Return on Equity (TTM)
-31.98

Latest News

Latest News

Nektar Therapeutics wins dismissal of investor lawsuit over cancer drug

A federal judge has dismissed a proposed class action accusing Nektar Therapeutics Inc of misleading investors about the results of clinical trials examining the effectiveness of its flagship cancer drug.

BRIEF-Nektar Therapeutics Announces Publication Of Results From Phase 1 Dose-Escalation Study In 'Cancer Discovery' Journal

* NEKTAR THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 1 DOSE-ESCALATION STUDY FOR BEMPEGALDESLEUKIN PLUS NIVOLUMAB IN 'CANCER DISCOVERY' JOURNAL Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics Reports First Quarter 2020 Financial Results

* Q1 REVENUE $50.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $47.6 MILLION

BRIEF-Nektar Therapeutics Reports Q4 Loss Per Share $0.64

* Q4 EARNINGS PER SHARE ESTIMATE $-0.68 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

Nektar withdraws application for opioid painkiller after FDA panel's vote

Nektar Therapeutics said on Tuesday it was withdrawing the application for its opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration (FDA) panel unanimously voted against the drug's approval.

U.S. FDA panel votes against approval for Nektar's opioid painkiller

Independent advisers to the U.S. Food and Drug Administration on Tuesday unanimously voted against Nektar Therapeutics' opioid painkiller for adults with chronic low back pain for whom currently available therapies have been inadequate.

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up